Literature DB >> 20228228

Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway.

George C Prendergast1, Richard Metz, Alexander J Muller.   

Abstract

Chronic inflammation drives the development of many cancers, but a genetic definition of what constitutes 'cancer-associated' inflammation has not been determined. Recently, a mouse genetic study revealed a critical role for the immune escape mediator indoleamine 2,3-dioxygenase (IDO) in supporting inflammatory skin carcinogenesis. IDO is generally regarded as being immunosuppressive; however, there was no discernable difference in generalized inflammatory processes in IDO-null mice under conditions where tumor development was significantly suppressed, implicating IDO as key to establishing the pathogenic state of 'cancer-associated' inflammation. Here we review recent findings and their potential implications to understanding the relationship between immune escape and inflammation in cancer. Briefly, we propose that genetic pathways of immune escape in cancer are synonymous with pathways that define 'cancer-associated' inflammation and that these processes may be identical rather than distinct, as generally presumed, in terms of their genetic definition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228228      PMCID: PMC2861073          DOI: 10.2353/ajpath.2010.091173

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Authors:  Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

2.  Heterotransplantation of a human malignant tumour to "Nude" mice.

Authors:  J Rygaard; C O Povlsen
Journal:  Acta Pathol Microbiol Scand       Date:  1969

3.  "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.

Authors:  R Kiessling; E Klein; H Pross; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

4.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

5.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

7.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

Review 8.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 9.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

10.  Inhibition of T cell proliferation by macrophage tryptophan catabolism.

Authors:  D H Munn; E Shafizadeh; J T Attwood; I Bondarev; A Pashine; A L Mellor
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  33 in total

Review 1.  Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases.

Authors:  G C Prendergast; M Y Chang; L Mandik-Nayak; R Metz; A J Muller
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Specific in situ detection of murine indoleamine 2, 3-dioxygenase.

Authors:  Sunil Thomas; James DuHadaway; George C Prendergast; Lisa Laury-Kleintop
Journal:  J Cell Biochem       Date:  2014-02       Impact factor: 4.429

Review 3.  Cancer immunotherapy: a promising dawn in cancer research.

Authors:  Banashree Bondhopadhyay; Sandeep Sisodiya; Atul Chikara; Asiya Khan; Pranay Tanwar; Dil Afroze; Neha Singh; Usha Agrawal; Ravi Mehrotra; Showket Hussain
Journal:  Am J Blood Res       Date:  2020-12-15

4.  Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis.

Authors:  Ping Gao; Jun-Lan Yang; Hong Zhao; Jun-Hao You; Yi Hu
Journal:  Tumour Biol       Date:  2014-07-15

5.  IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.

Authors:  Richard Metz; Courtney Smith; James B DuHadaway; Phillip Chandler; Babak Baban; Lauren M F Merlo; Elizabeth Pigott; Martin P Keough; Sonja Rust; Andrew L Mellor; Laura Mandik-Nayak; Alexander J Muller; George C Prendergast
Journal:  Int Immunol       Date:  2014-01-08       Impact factor: 4.823

6.  Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models.

Authors:  P Vandenabeele; S Grootjans; N Callewaert; N Takahashi
Journal:  Cell Death Differ       Date:  2012-11-30       Impact factor: 15.828

Review 7.  Initiation and execution mechanisms of necroptosis: an overview.

Authors:  Sasker Grootjans; Tom Vanden Berghe; Peter Vandenabeele
Journal:  Cell Death Differ       Date:  2017-05-12       Impact factor: 15.828

8.  Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase.

Authors:  Mee Young Chang; Courtney Smith; James B DuHadaway; Jennifer R Pyle; Janette Boulden; Alejandro Peralta Soler; Alexander J Muller; Lisa D Laury-Kleintop; George C Prendergast
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

9.  Individual differences in pre-carcinogen cytokine and corticosterone concentrations and depressive-like behavior predict tumor onset in rats exposed to a carcinogen.

Authors:  Leah M Pyter; Brian J Prendergast
Journal:  Psychoneuroendocrinology       Date:  2012-10-06       Impact factor: 4.905

10.  Human indoleamine 2,3-dioxygenase is a catalyst of physiological heme peroxidase reactions: implications for the inhibition of dioxygenase activity by hydrogen peroxide.

Authors:  Mohammed Freewan; Martin D Rees; Tito S Sempértegui Plaza; Elias Glaros; Yean J Lim; Xiao Suo Wang; Amanda W S Yeung; Paul K Witting; Andrew C Terentis; Shane R Thomas
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.